Physiology and pathophysiology of incretins in the kidney

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 1, 2014, Pages 54-60

  Von Websky, Karoline ^a,b   Reichetzeder, Christoph ^a,b   Hocher, Berthold ^a  

^a UNIVERSITY OF POTSDAM   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

DDP 4 inhibition; diabetes; diabetic nephropathy; GLP 1 receptor; hypertension; incretins, kidney; renal impairment

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN;

ALBUMINURIA; GLOMERULOSCLEROSIS; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCRETINS; KIDNEY; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84890518591     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000437542.77175.a0     Document Type: Review

References (73)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157.
2. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem FEBS 1993; 214:829-835.
3. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011; 33:511-527.
4. Masajtis-Zagajewska A, Kurnatowska I, Wajdlich M, et al. Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and nondiabetic patients. Int Urol Nephrol 2013. [Epub ahead of print]
5. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134:2156-2164.
6. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141:120-128.
7. Pezeshki A, Muench GP, Chelikani PK. Short communication: Expression of peptide YY, proglucagon, neuropeptide Y receptor Y2, and glucagon-like peptide-1 receptor in bovine peripheral tissues. J Dairy Sci 2012; 95:5089-5094.
8. Ko rner M, Sto ckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med Off Publ Soc Nucl Med 2007; 48:736-743.
9. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-
10. Am J Physiol Renal Physiol 2011; 301:F355-F363.
11. Jackson EK, Kochanek SJ, Gillespie DG. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 2012; 60:757-764.
12. Kettmann U, Humbel B, Holzhausen HJ. Ultrastructural localization of dipeptidyl peptidase IV in the glomerulum of the rat kidney. Acta Histochem 1992; 92:225-227.
13. Mentlein R. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides. Regul Pept 1999; 85:9-24.
14. Tiruppathi C, Miyamoto Y, Ganapathy V, et al. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem 1990; 265:1476-1483.
15. Tagore DM, Nolte WM, Neveu JM, et al. Peptidase substrates via global peptide profiling. Nat Chem Biol 2009; 5:23-25.
16. Girardi ACC, Fukuda LE, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition downregulates Na-H exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008; 294:F414-F422.
17. Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 2012; 303:F963-F971. Interestingly, the studies from Rieg et al. are indicating that alogliptin-induced natriuresis and diuresis are in part independent of the GLP1 receptor.
18. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagonlike peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21:1125-1135.
19. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002; 434:163-167.
20. Gutzwiller J-P, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 2006; 73:142-150.
21. Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89:3055-3061.
22. Carraro-Lacroix LR, Malnic G, Girardi ACC. Regulation of Na/Hexchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 2009; 297:F1647-F1655.
23. Lone AM, Nolte WM, Tinoco AD, Saghatelian A. Peptidomics of the prolyl peptidases. AAPS J 2010; 12:483-491.
24. Lambeir A-M, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40:209-294.
25. Hartel S, Gossrau R, Hanski C, Reutter W. Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988; 89:151-161.
26. Hartel-Schenk S, Gossrau R, Reutter W. Comparative immunohistochemistry and histochemistry of dipeptidyl peptidase IV in rat organs during development. Histochem J 1990; 22:567-578.
27. Stefanovic V, Ardaillou N, Vlahovic P, et al. Interferon-gamma induces dipeptidyl peptidase IV expression in human glomerular epithelial cells. Immunology 1993; 80:465-470.
28. Yang J, Campitelli J, Hu G, et al. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007; 81:272-279.
29. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: Mechanisms of renal disease progression. Exp Biol Med Maywood NJ 2008; 233:4-11.
30. Mitic B, Lazarevic G, Vlahovic P, et al. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidyl peptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail 2008; 30:896-903.
31. Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2010; 2:594-606.
32. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013; 154:127-139.
33. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA. Chronic renal failure: Effect of hemodialysis on gastrointestinal hormones. Am J Surg 1984; 148:732-735.
34. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 1992; 74:379-384.
35. Hegbrant J, Thysell H, Ekman R. Plasma levels of gastrointestinal regulatory peptides in patients receiving maintenance hemodialysis. Scand J Gastroenterol 1991; 26:599-604.
36. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53:654-662.
37. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008; 117:2340-2350.
38. Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88:1772-1779.
39. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006; 49:706-712.
40. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64:317-327.
41. Brown DX, Evans M. Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: A pharmacological perspective. J Nutr Metab 2012; 2012: 381713.
42. Malm-Erjefa lt M, Bjørnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos Biol Fate Chem 2010; 38:1944-1953.
43. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009; 68:898-905.
44. Byetta (exenatide injection). Prescribing information. http://pi.lilly.com/us/byetta-pi.pdf. [Accessed 2 November 2008]
45. Chan JCN, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10:545-555.
46. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65:1230-1239.
47. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review. Diabetes Obes Metab 2011; 13:7-18.
48. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos Biol Fate Chem 2010; 38:667-678.
49. Friedrich C, Emser A, Woerle H-J, Graefe-Mody U. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther 2013. [Epub ahead of print]
50. Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCb activation in diabetes. Diabetes 2012; 61:2967-2979. The authors found that renal protective effects of GLP-1 might be mediated via the inhibition of Ang II actions and diminished by diabetes because of PKCb activation and the increased degradation of GLP-1R in the glomerular endothelial cells.
51. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18:1227-1238.
52. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54:965-978.
53. Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61:1422-1434.
54. Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end productinduced protein arginine methyltranferase-1 expression. Am J Pathol 2013; 182:132-141.
55. Yang H, Li H, Wang Z, et al. Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat. J Surg Res 2013. [Epub ahead of print]
56. Li W, Cui M, Wei Y, et al. Inhibition of the expression of TGF-b1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2012; 30:749-757.
57. Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res 2012; 84:395-398.
58. Hirata K, Kume S, Araki S, et al. Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380:44-49.
59. Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006; 103:17985-17990.
60. Liu Q, Adams L, Broyde A, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010; 9:32.
61. Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol 2013; 304:F137-F144.
62. Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: A streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009; 200:53-61.
63. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012; 340:248-255.
64. Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011: 162092.
65. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36:119-130. This experiment is important, as it indicates that linagliptin on top of an Ang II receptor blocker may offer a new therapeutic approach for patients with diabetic nephropathy who do not adequately respond to angiotensin 2 receptor blocker treatment.
66. Groop P-H, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36:3460-3468.
67. Boehringer Ingelheim Pharmaceuticals. MARLINA: Efficacy, safety and modification of albuminuria in type 2 diabetes subjects with renal disease with linagliptin. In ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated May 15 2013]. http://www. clinicaltrials.gov/ct2/show/NCT01792518. NLM identifier: NCT01792518. [Accessed 29 May 2013]
68. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors: From preclinical development to clinical research. Kidney Blood Press Res 2012; 36:65-84.
69. Chaykovska L, Alter ML, von Websky K, et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens 2013; 31:2290-2299.
70. Pacheco BP, Crajoinas RO, Couto GK, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29:520-528.
71. Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 2012; 14:14-21.
72. Girardi AC, Degray BC, Nagy T, et al. Association of Na()-H() exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001; 276:46671-46677.
73. Girardi ACC, Knauf F, Demuth H-U, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Na/H exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol 2004; 287:C1238-C1245.